Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226341 · ClinicalTrials.gov registry record · Phase 4
ACTHar in the Treatment of Lupus Nephritis
A Phase 4 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT02226341 is a Phase 4 study that was terminated before completion, run by Columbia University. The registered enrollment target is 8 participants.
The verdict
NCT02226341, a Phase 4 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
Systemic Lupus Erythematosus (SLE) is a disease in which the immune system attacks the healthy cells and tissues, causing inflammation that can damage organs in the body. About 50% of SLE patients experience inflammation in the kidneys. The purpose of this study is to determine the effectiveness and safety of two dosing arms of ACTHar gel in treating proliferative Lupus Nephritis (LN). This study hypothesizes that both dosing arms of ACTHar are safe and effective in treating proliferative LN (Class III and IV).
Interventions
- DRUG CellCept
- DRUG ACTHar gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-10 |
| Est. Completion | 2024-01-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226341
The ClinicalTrials.gov registry entry for NCT02226341 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CellCept is the first listed.
NCT02226341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02226341 about?
NCT02226341 is a clinical study titled "ACTHar in the Treatment of Lupus Nephritis". Systemic Lupus Erythematosus (SLE) is a disease in which the immune system attacks the healthy cells and tissues, causing inflammation that can damage organs in the body. About 50% of SLE patients experience inflammation in the kidneys. The purpose of this study is to determine the effectiveness and...
What is the current status of trial NCT02226341?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2014-10. Estimated completion is 2024-01-03.
What interventions are being tested in trial NCT02226341?
The interventions under investigation include: CellCept (DRUG), ACTHar gel (DRUG).
Who is sponsoring clinical trial NCT02226341?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.